Hemato Oncology Testing Market Report 2026

Hemato Oncology Testing Market Overview

• Hemato Oncology Testing market size has reached to $3.93 billion in 2025 • Expected to grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 14.6% • Growth Driver: The Increasing Incidence Of Hematologic Cancer Fueling Market Growth Due To Rising Disease Burden • Market Trend: NeoGenomics Launches AML Express for Enhanced AML Detection and Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hemato Oncology Testing Market?

Hemato oncology testing refers to a diagnostic test that is carried out to detect the presence of symptoms of blood disorders and blood cancers. These tests are used to diagnose anemia, infection, hemophilia, blood clotting disorders, and leukemia. The main products and services of hemato oncology testing are assay kits and reagents and services. Assay kits and reagents refer to instruments and chemicals that are used together to carry out analysis of certain substances. The cancer types involved are leukemia, lymphoma, multiple myeloma, and others which are tested by polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other technologies by hospitals, academic and research institutes, and other end-users.

What Is The Hemato Oncology Testing Market Growth Forecast?

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in genomic testing infrastructure, expansion of AI-driven diagnostic platforms, growing demand for companion diagnostics, continuous innovation in assay technologies. Major trends in the forecast period include increasing adoption of molecular diagnostic testing, rising use of next-generation sequencing in oncology, growing demand for personalized cancer diagnostics, expansion of automated laboratory testing platforms, enhanced integration of data analytics in hemato-oncology.

Global Hemato Oncology Testing Market Segmentation

1) By Product And Services: Assay Kits And Reagents, Services 2) By Cancer Type: Leukemia, Lymphoma, Multiple Myeloma 3) By Technology: Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS) 4) By End User: Hospitals, Academic And Research Institutes Subsegments: 1) By Assay Kits And Reagents: PCR Kits, Next-Generation Sequencing (NGS) Kits, Flow Cytometry Reagents, Antibodies 2) By Services: Testing Services, Data Analysis Services

What Is The Driver Of The Hemato Oncology Testing Market?

The increasing incidence of hematologic cancer is expected to drive the growth of the hemato oncology testing market going forward. Hematologic cancer refers to a group of cancers that originate in the blood and affect the blood, bone marrow, and lymphatic system and include diseases such as leukemia, lymphoma, and myeloma. These diseases can be reduced with an early diagnosis which can be achieved using hemato oncology testing. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, From 2024 to 2026, the incidence rate of leukemia in the UK is estimated at approximately 17.9 cases per 100,000 people per year, and it is projected to decrease by 3% to around 17.4 per 100,000 by 2038 to 2040. Therefore, the increasing incidence of hematologic cancer is driving the growth of the hemato-oncology testing market.

Key Players In The Global Hemato Oncology Testing Market

Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

Global Hemato Oncology Testing Market Trends and Insights

Major companies operating in the hemato-oncology testing market are introducing new innovations such as next-generation sequencing (NGS) to improve the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and facilitate personalized treatment strategies tailored to individual patient needs. Next-generation sequencing (NGS) is a high-throughput DNA sequencing technology that allows for the rapid and cost-effective analysis of entire genomes or targeted regions of DNA. For instance, in October 2024, NeoGenomics Inc., a US-based cancer diagnostics and genomic testing company launched AML Express, a next-generation sequencing (NGS) tool designed for the rapid detection of mutations associated with Acute Myeloid Leukemia (AML). This advanced diagnostic platform offers high accuracy and quick turnaround, supporting oncologists in making timely, targeted treatment decisions. AML Express aims to improve patient outcomes by providing precise mutation insights tailored to AML-specific genetic profiles.

What Are Latest Mergers And Acquisitions In The Hemato Oncology Testing Market?

In January 2023, Merck & Co. Inc. a US-based pharmaceutical company acquired Imago BioSciences Inc. for $1.35 billion. With this acquisition, Merck continued its strategy of investing in its pipeline to strengthen its presence in the field of hematology. Imago BioSciences Inc. is a US-based biotechnology company developing diagnostic and therapeutic products for hemato oncology testing and other blood-related disorders.

Regional Outlook

North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Hemato Oncology Testing Market?

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.